Wedge Resection for Ground-glass Opacity-featured Lung Cancer (ECTOP-1020) (NCT06102161) | Clinical Trial Compass
Not Yet RecruitingPhase 3
Wedge Resection for Ground-glass Opacity-featured Lung Cancer (ECTOP-1020)
China286 participantsStarted 2023-11
Plain-language summary
This is a clinical trial from the Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1020. The goal of this clinical trial is to confirm the therapeutic effect of Wedge resection for ground-glass opacity-featured lung cancer with a size less than 2cm and a consolidation-to-tumor ratio between 0.25 to 0.5.
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Patients who sign the informed consent form and are willing to complete the study according to the plan;
✓. Aged from 18 to 80 years old;
✓. ECOG equals 0 or 1;
✓. Not receiving lung cancer surgery before;
✓. Intraoperative or postoperative pathologic diagnosis of lung adenocarcinoma;
✓. Single lung nodules with ground-glass dominant or pure ground-glass on CT, or multiple lung nodules with the major lesion being the aforementioned nodules;
✓. The nodule has a consolidation-to-tumor ratio (CTR) between 0.25 and 0.5 (including 0.25 and 0.5), and the nodule size is less than or equal to 2 cm;
✓. peripheral type of nodes, namely, nodes in the outer 1/3 of the lung field.
Exclusion criteria
✕. Postoperative pathologic diagnosis of adenocarcinoma in situ or minimally invasive adenocarcinoma.
✕. CTR is not between 0.25-0.5 or nodule size greater than 2 cm;
✕. Cannot be completely resected by wedge resection;
✕. Invasive lung adenocarcinoma or lung malignancy other than lung adenocarcinoma diagnosed cytologically or pathologically;